People who received Johnson & Johnson’s Covid-19 vaccine may benefit from a booster dose of Pfizer or Moderna, preliminary results of a US study published Wednesday showed.
The study, funded by the National Institutes of Health (NIH), was eagerly awaited in the United States because it looked at the possibility of mixing Covid-19 vaccines using a different vaccine than the initial doses for the booster shot, which is not currently allowed in the country.
The study was conducted on 458 adults who had been vaccinated with one of three US-approved brands (Pfizer, Moderna, and J&J) for at least 12 weeks. Researchers then analyzed antibody levels 15 days after the booster shot.
Antibody levels for those who had originally received Moderna shots were higher “irrespective of the booster vaccine administered,” when compared with those who had initially received Pfizer or J&J, the study said. It also said that no safety concerns were identified after booster doses were administered.
The study is expected to fuel discussions by a US Food and Drug Administration (FDA) expert committee, which is scheduled to consider applications for a booster dose from Moderna and J&J. However, the study is yet to be peer-reviewed.
The study, funded by the National Institutes of Health (NIH), was eagerly awaited in the United States because it looked at the possibility of mixing Covid-19 vaccines using a different vaccine than the initial doses for the booster shot, which is not currently allowed in the country.
The study was conducted on 458 adults who had been vaccinated with one of three US-approved brands (Pfizer, Moderna, and J&J) for at least 12 weeks. Researchers then analyzed antibody levels 15 days after the booster shot.
Antibody levels for those who had originally received Moderna shots were higher “irrespective of the booster vaccine administered,” when compared with those who had initially received Pfizer or J&J, the study said. It also said that no safety concerns were identified after booster doses were administered.
The study is expected to fuel discussions by a US Food and Drug Administration (FDA) expert committee, which is scheduled to consider applications for a booster dose from Moderna and J&J. However, the study is yet to be peer-reviewed.
